Na Li

6.1k total citations · 5 hit papers
112 papers, 3.4k citations indexed

About

Na Li is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Na Li has authored 112 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Molecular Biology, 33 papers in Oncology and 27 papers in Cancer Research. Recurrent topics in Na Li's work include RNA modifications and cancer (32 papers), Ferroptosis and cancer prognosis (21 papers) and Cancer-related molecular mechanisms research (21 papers). Na Li is often cited by papers focused on RNA modifications and cancer (32 papers), Ferroptosis and cancer prognosis (21 papers) and Cancer-related molecular mechanisms research (21 papers). Na Li collaborates with scholars based in China, United States and United Kingdom. Na Li's co-authors include Darrell J. Irvine, Haoyi Wang, Xingying Zhang, Xiaofei Wei, Wei Mu, Weidong Han, Xianquan Zhan, Mariane B. Melo, Li Tang and Yiran Zheng and has published in prestigious journals such as Science, Cell and Journal of Clinical Oncology.

In The Last Decade

Na Li

103 papers receiving 3.4k citations

Hit Papers

Enhancing T cell therapy through TCR-signaling-responsive... 2015 2026 2018 2022 2018 2015 2019 2020 2023 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
    2018 542 citations Li Tang, Yiran Zheng et al. Nature Biotechnology profile →
  2. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
    2015 425 citations Na Li et al. Cancer Research profile →
  3. Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor
    2019 319 citations Leyuan Ma, Tanmay Dichwalkar et al. Science profile →
  4. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors
    2020 293 citations Na Tang, Chen Cheng et al. JCI Insight profile →
  5. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
    2023 128 citations Leyuan Ma, Wuhbet Abraham et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Na Li China 25 1.9k 1.6k 1.0k 890 510 112 3.4k
Bryan D. Choi United States 29 2.5k 1.3× 1.1k 0.7× 1.2k 1.2× 884 1.0× 652 1.3× 105 4.2k
Vijay Bhoj United States 17 2.0k 1.1× 916 0.6× 1.3k 1.3× 521 0.6× 586 1.1× 39 3.4k
Omkar U. Kawalekar United States 13 3.1k 1.7× 1.3k 0.8× 1.8k 1.8× 1.1k 1.3× 768 1.5× 20 4.5k
Gwenn Danet-Desnoyers United States 21 1.6k 0.9× 1.2k 0.8× 1.1k 1.1× 408 0.5× 711 1.4× 38 3.1k
Leonid S. Metelitsa United States 34 2.8k 1.5× 1.2k 0.7× 2.6k 2.6× 570 0.6× 617 1.2× 57 4.6k
Reno Debets Netherlands 44 4.1k 2.2× 1.7k 1.1× 3.1k 3.1× 782 0.9× 1.4k 2.8× 161 6.2k
Linda M. Pilarski Canada 43 1.2k 0.6× 2.9k 1.9× 1.2k 1.2× 606 0.7× 215 0.4× 173 5.6k
Benjamin G. Vincent United States 34 2.6k 1.4× 1.7k 1.1× 3.0k 3.0× 874 1.0× 255 0.5× 104 5.3k
Richard P. Junghans United States 41 2.4k 1.3× 2.0k 1.2× 2.4k 2.4× 559 0.6× 753 1.5× 99 5.7k

Countries citing papers authored by Na Li

Since Specialization
Citations

This map shows the geographic impact of Na Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Na Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Na Li more than expected).

Fields of papers citing papers by Na Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Na Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Na Li. The network helps show where Na Li may publish in the future.

Co-authorship network of co-authors of Na Li

This figure shows the co-authorship network connecting the top 25 collaborators of Na Li. A scholar is included among the top collaborators of Na Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Na Li. Na Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Na, et al.. (2026). SREBP-1 increases glucose uptake to promote tumor resistance to lysosome inhibition. Science Translational Medicine. 18(834). eadx6873–eadx6873.
2.
3.
Yu, Wenqian, et al.. (2024). The PRC2 complex epigenetically silences GATA4 to suppress cellular senescence and promote the progression of breast cancer. Translational Oncology. 46. 102014–102014. 3 indexed citations
4.
5.
Ma, Zhigang, Min Fang, Xiaojun Ding, et al.. (2024). Screening of Bovine Coronavirus Multiepitope Vaccine Candidates: An Immunoinformatics Approach. Transboundary and Emerging Diseases. 2024(1). 5986893–5986893. 3 indexed citations
6.
Pan, Yating, et al.. (2024). Disulfiram/Cu targeting FOXO6 modulates sensitivity of hepatocellular carcinoma to lenvatinib via disrupt choline metabolic. Cellular Signalling. 127. 111563–111563. 1 indexed citations
7.
Li, Na, et al.. (2023). Attitudes and perceptions of cancer patients and healthcare providers towards prehabilitation: A thematic synthesis. British Journal of Health Psychology. 29(2). 395–429. 4 indexed citations
8.
Li, Na, et al.. (2023). Fatal Cytokine-Release Syndrome in A Patient Receiving Toripalimab: A Case Report. Immunotherapy. 15(9). 641–645. 4 indexed citations
9.
10.
Hu, Yan, et al.. (2022). Long noncoding RNAMEG3 inhibits oral squamous cell carcinoma progression via GATA3. FEBS Open Bio. 13(1). 195–208. 10 indexed citations
11.
Li, Jingwen, Xi Long, Qing Zhang, et al.. (2022). Pearson’s patterns correlational of clinical risks at admissions with hospitalization outcomes during initial COVID-19 outbreak. iScience. 25(6). 104415–104415. 1 indexed citations
12.
Zhang, Huiyuan, Yazhen Wang, Ying Ma, et al.. (2022). Increased CD4+CD8+ Double Positive T Cells during Hantaan Virus Infection. Viruses. 14(10). 2243–2243. 9 indexed citations
13.
Fan, Lichao, Huan Liu, Na Li, et al.. (2021). Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered. Medicine. 100(2). e23923–e23923. 9 indexed citations
14.
Nouri, Mannan, Josselin Caradec, Amy A. Lubik, et al.. (2020). Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer. Clinical Cancer Research. 26(7). 1678–1689. 29 indexed citations
15.
Li, Na, et al.. (2020). T‐cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: A methodology and clinical applications. Cancer Communications. 40(10). 473–483. 27 indexed citations
16.
Tang, Na, Chen Cheng, Xingying Zhang, et al.. (2020). TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 5(4). 293 indexed citations breakdown →
17.
Ma, Leyuan, Tanmay Dichwalkar, Jason Y.H. Chang, et al.. (2019). Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 365(6449). 162–168. 319 indexed citations breakdown →
18.
Geng, Feng, Mingjun Fan, Juan Li, et al.. (2019). Knockdown of METTL14 inhibits the growth and invasion of cervical cancer. Translational Cancer Research. 8(6). 2307–2315. 1 indexed citations
19.
Alam, Hunain, Na Li, Shilpa S. Dhar, et al.. (2018). HP1γ Promotes Lung Adenocarcinoma by Downregulating the Transcription-Repressive Regulators NCOR2 and ZBTB7A. Cancer Research. 78(14). 3834–3848. 61 indexed citations
20.
Tang, Li, Yiran Zheng, Mariane B. Melo, et al.. (2018). Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nature Biotechnology. 36(8). 707–716. 542 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bryan D. Choi Breakdown of academic impact, for papers by Vijay Bhoj Breakdown of academic impact, for papers by Omkar U. Kawalekar Breakdown of academic impact, for papers by Gwenn Danet-Desnoyers Breakdown of academic impact, for papers by Leonid S. Metelitsa Breakdown of academic impact, for papers by Reno Debets Breakdown of academic impact, for papers by Linda M. Pilarski Breakdown of academic impact, for papers by Benjamin G. Vincent Breakdown of academic impact, for papers by Richard P. Junghans
Rankless by CCL
2026